PKA Inhibitors
SEE ALSO...
Items 51 to 54 of 54 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
N-[2-(p-Cinnamylamino)ethyl]-5-isoquinolone Sulfonamide | 130964-40-8 | sc-207932 | 10 mg | $260.00 | ||
N-[2-(p-Cinnamylamino)ethyl]-5-isoquinolone Sulfonamide acts as a potent PKA modulator, characterized by its ability to induce conformational changes in the enzyme. This compound exhibits unique electrostatic interactions that facilitate substrate recognition and binding. Its reaction kinetics demonstrate a notable increase in turnover rates, promoting efficient signal transduction. Furthermore, the compound's amphiphilic nature enhances membrane permeability, allowing for effective cellular uptake and localized action. | ||||||
AT7867 | 857531-00-1 | sc-364417 sc-364417A | 10 mg 50 mg | $450.00 $1300.00 | 1 | |
AT7867 is a selective PKA activator distinguished by its unique binding affinity, which enhances the enzyme's catalytic efficiency. This compound engages in specific hydrogen bonding and hydrophobic interactions, stabilizing the enzyme-substrate complex. Its kinetic profile reveals a rapid onset of action, allowing for immediate modulation of downstream signaling pathways. Additionally, AT7867's solubility characteristics contribute to its effective distribution within cellular compartments, influencing its overall bioavailability. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK 690693 functions as a selective PKA inhibitor, distinguished by its ability to disrupt the enzyme's regulatory subunit interactions. This compound exhibits unique hydrophobic interactions that stabilize its binding, leading to altered phosphorylation patterns. Its kinetic profile reveals a competitive inhibition mechanism, significantly affecting downstream signaling pathways. Additionally, GSK 690693's structural flexibility allows for dynamic conformational adjustments, enhancing its specificity in targeting PKA isoforms. | ||||||
PKI (14-22) amide (myristoylated) | 201422-03-9 | sc-471154 | 0.5 mg | $132.00 | 2 | |
PKI (14-22) amide, myristoylated, acts as a potent PKA inhibitor by mimicking the natural substrate, effectively competing for binding sites. Its myristoylation enhances membrane affinity, facilitating localized action within lipid environments. The compound's unique structural features promote specific interactions with PKA's active site, leading to a distinct modulation of enzymatic activity. This results in altered phosphorylation dynamics, influencing various cellular signaling cascades. | ||||||